FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010487908> ?p ?o ?g. }

• W2010487908 endingPage "575" @default.
• W2010487908 startingPage "570" @default.
• W2010487908 abstract "The aim of this study is to examine Her-2/neu gene amplification and protein overexpression in a spectrum of ovarian neoplasms using both immunohistochemical (IHC) and fluorescence in situ hybridization (FISH) techniques that are FDA approved. This study is focused on early stage tumors including both carcinomas and borderline tumors.FDA-approved IHC and FISH for Her-2/neu were performed on formalin-fixed, paraffin-embedded tissue from 79 ovarian neoplasms representing a broad spectrum of tumor types as well as four normal ovaries. All tumors were either stage I or stage II. Tumor and normal tissue were studied collectively using a tissue microarray (TMA). HercepTest (DAKO) and PathVysion Her-2/neu probe kit (Vysis Inc.) were used for IHC and FISH analysis.FISH analysis of serous carcinomas demonstrated Her-2/neu gene amplification in 3 (18%) of 17 cases. Two of three cases showing Her-2/neu gene amplification were scored 1+ using IHC, while the remaining case was scored as 0. Analysis of endometrioid carcinomas demonstrated Her-2/neu amplification using FISH in 1 of 10 (10%) cases. IHC in this case was scored 2+ (positive). None of the remaining 44 tumors, including clear cell carcinoma (n = 12), transitional cell carcinoma (n = 1), mixed epithelial carcinoma (n = 7), carcinoma not otherwise specified (n = 1), and 31 borderline tumors (mucinous, n = 17; endometrioid, n = 7; serous, n = 7), showed Her-2/neu gene amplification or protein overexpression. Normal ovaries were negative as well.Amplification of Her-2/neu in early stage ovarian neoplasms is infrequent, 6.7% overall. Due to the limited number of informative cases, we were unable to determine the clinical significance of Her-2/neu amplification in this study. Her-2/neu amplification was restricted to carcinomas and was not encountered in ovarian borderline tumors." @default.
• W2010487908 created "2016-06-24" @default.
• W2010487908 creator A5046956876 @default.
• W2010487908 creator A5053542215 @default.
• W2010487908 creator A5065670005 @default.
• W2010487908 creator A5074638556 @default.
• W2010487908 creator A5077459187 @default.
• W2010487908 date "2004-12-01" @default.
• W2010487908 modified "2023-09-30" @default.
• W2010487908 title "Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms" @default.
• W2010487908 cites W1573011590 @default.
• W2010487908 cites W1966996035 @default.
• W2010487908 cites W1978082129 @default.
• W2010487908 cites W1986314326 @default.
• W2010487908 cites W1998606142 @default.
• W2010487908 cites W2006087610 @default.
• W2010487908 cites W2006621710 @default.
• W2010487908 cites W2011945440 @default.
• W2010487908 cites W2014920648 @default.
• W2010487908 cites W2017953079 @default.
• W2010487908 cites W2031474650 @default.
• W2010487908 cites W2035184902 @default.
• W2010487908 cites W2040048828 @default.
• W2010487908 cites W2051566114 @default.
• W2010487908 cites W2062051005 @default.
• W2010487908 cites W2065071195 @default.
• W2010487908 cites W2068120868 @default.
• W2010487908 cites W2070995329 @default.
• W2010487908 cites W2077145295 @default.
• W2010487908 cites W2078159546 @default.
• W2010487908 cites W2083997119 @default.
• W2010487908 cites W2093070947 @default.
• W2010487908 cites W2125730396 @default.
• W2010487908 cites W2128313210 @default.
• W2010487908 cites W2137223606 @default.
• W2010487908 cites W2156544288 @default.
• W2010487908 cites W4253200803 @default.
• W2010487908 doi "https://doi.org/10.1016/j.ygyno.2004.08.043" @default.
• W2010487908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15581965" @default.
• W2010487908 hasPublicationYear "2004" @default.
• W2010487908 type Work @default.
• W2010487908 sameAs 2010487908 @default.
• W2010487908 citedByCount "31" @default.
• W2010487908 countsByYear W20104879082012 @default.
• W2010487908 countsByYear W20104879082013 @default.
• W2010487908 countsByYear W20104879082014 @default.
• W2010487908 countsByYear W20104879082015 @default.
• W2010487908 countsByYear W20104879082021 @default.
• W2010487908 countsByYear W20104879082023 @default.
• W2010487908 crossrefType "journal-article" @default.
• W2010487908 hasAuthorship W2010487908A5046956876 @default.
• W2010487908 hasAuthorship W2010487908A5053542215 @default.
• W2010487908 hasAuthorship W2010487908A5065670005 @default.
• W2010487908 hasAuthorship W2010487908A5074638556 @default.
• W2010487908 hasAuthorship W2010487908A5077459187 @default.
• W2010487908 hasConcept C104317684 @default.
• W2010487908 hasConcept C121608353 @default.
• W2010487908 hasConcept C126322002 @default.
• W2010487908 hasConcept C142724271 @default.
• W2010487908 hasConcept C146357865 @default.
• W2010487908 hasConcept C150173356 @default.
• W2010487908 hasConcept C151730666 @default.
• W2010487908 hasConcept C193270364 @default.
• W2010487908 hasConcept C204232928 @default.
• W2010487908 hasConcept C2776872082 @default.
• W2010487908 hasConcept C2777542201 @default.
• W2010487908 hasConcept C2777546739 @default.
• W2010487908 hasConcept C2777632260 @default.
• W2010487908 hasConcept C2780427987 @default.
• W2010487908 hasConcept C3019054536 @default.
• W2010487908 hasConcept C30481170 @default.
• W2010487908 hasConcept C530470458 @default.
• W2010487908 hasConcept C55493867 @default.
• W2010487908 hasConcept C71924100 @default.
• W2010487908 hasConcept C7602840 @default.
• W2010487908 hasConcept C86803240 @default.
• W2010487908 hasConceptScore W2010487908C104317684 @default.
• W2010487908 hasConceptScore W2010487908C121608353 @default.
• W2010487908 hasConceptScore W2010487908C126322002 @default.
• W2010487908 hasConceptScore W2010487908C142724271 @default.
• W2010487908 hasConceptScore W2010487908C146357865 @default.
• W2010487908 hasConceptScore W2010487908C150173356 @default.
• W2010487908 hasConceptScore W2010487908C151730666 @default.
• W2010487908 hasConceptScore W2010487908C193270364 @default.
• W2010487908 hasConceptScore W2010487908C204232928 @default.
• W2010487908 hasConceptScore W2010487908C2776872082 @default.
• W2010487908 hasConceptScore W2010487908C2777542201 @default.
• W2010487908 hasConceptScore W2010487908C2777546739 @default.
• W2010487908 hasConceptScore W2010487908C2777632260 @default.
• W2010487908 hasConceptScore W2010487908C2780427987 @default.
• W2010487908 hasConceptScore W2010487908C3019054536 @default.
• W2010487908 hasConceptScore W2010487908C30481170 @default.
• W2010487908 hasConceptScore W2010487908C530470458 @default.
• W2010487908 hasConceptScore W2010487908C55493867 @default.
• W2010487908 hasConceptScore W2010487908C71924100 @default.
• W2010487908 hasConceptScore W2010487908C7602840 @default.
• W2010487908 hasConceptScore W2010487908C86803240 @default.
• W2010487908 hasIssue "3" @default.

• next